Methylation & Detox SNPs (MTHFR, COMT, GST)

Navigation & Literature

• Parent Silo: 03 - Diagnostics & Quantified Self MOC
• Literature Dossier: Methylation & Detox SNPs (MTHFR, COMT, GST) - References

---

1. Genotype vs. Phenotypic Target Matrix

Gene & SNP (rsID)	Standard / Wild-Type Allele	Variant Risk Allele & Functional Impact	Phenotypic Validation Biomarker & Optimal Target
MTHFR C677T (rs1801133)	C/C ($100\%$ enzymatic activity)	C/T ($\sim 65\%$ activity) / T/T ($\sim 30\%$ activity; thermolabile FAD binding)	Plasma Homocysteine $5.0–7.0\mu \text{mol/L}$ & RBC Folate $>500\text{ ng/mL}$
MTHFR A1298C (rs1801131)	A/A ($100\%$ activity)	A/C or C/C ($15–30\%$ reduction; compound 677T/1298C $\sim 40–50\%$ loss)	Serum/CSF BH4 (Tetrahydrobiopterin) & Homocysteine $<7.0\mu \text{mol/L}$
COMT Val158Met (rs4680)	G/G (Val/Val: “Warrior” fast catecholamine clearance)	A/A (Met/Met: “Worrier” $3–4\times$ lower activity; high prefrontal dopamine/estrogen)	Urinary/Plasma Metanephrines & 2-Methoxyestradiol ($2{\text{-MeOE}}_2$)
MTR A2756G (rs1805087) & MTRR A66G (rs1801394)	A/A (normal methionine synthase B12 cycling)	G/G (increased B12 oxidation / impaired reductive reactivation of cobalamin)	Active B12 (Holotranscobalamin) $>70\text{ pmol/L}$ & MMA $<150\text{ nmol/L}$
PEMT (rs7946 / rs12325817)	C/C (normal estrogen-inducible phosphatidylcholine synthesis)	T/T (impaired hepatic de novo choline synthesis; high risk of MASLD on low-choline diet)	Normal ALT ($<20\text{ U/L}$) & Plasma Choline / Betaine ratio
GSTM1 / GSTT1 (Copy Number) & GSTP1 (rs1695)	Present (+/+) / A/A (Ile/Ile)	Null deletion (-/-) or G/G (Val/Val): reduced Phase II glutathione conjugation	GGT $<18\text{ U/L}$, Reduced:Oxidized Glutathione (GSH:GSSG $>10:1$)
SOD2 Val16Ala (rs4880)	C/T balanced mitochondrial targeting	T/T (Val/Val: $30–40\%$ lower mitochondrial import of Mn-SOD)	Urinary 8-OHdG (oxidative DNA damage) & F2-Isoprostanes

---

2. Physiological Significance & Mechanistic Architecture

One-Carbon Metabolism & The Riboflavin (FAD) Rescue of MTHFR C677T

Methylenetetrahydrofolate reductase (MTHFR) catalyzes the irreversible reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF), the primary methyl donor required by methionine synthase (MTR) to remethylate homocysteine into methionine and subsequently S-adenosylmethionine (SAMe).

• Biochemical Mechanism of C677T (rs1801133): The Alanine-to-Valine substitution at codon 222 (Ala222Val) weakens the binding affinity of the MTHFR enzyme for its essential flavin cofactor, FAD (flavin adenine dinucleotide, derived from Vitamin B2 / Riboflavin). When intracellular FAD drops, the 677T/T enzyme dissociates into monomers and loses 70% of its catalytic activity.
• Vascular & Neurological Hazard: Uncompensated 677T/T homozygosity elevates plasma homocysteine, conferring a $1.25\times \text{ to }1.87\times$ higher risk of ischemic stroke and hypertension—an effect that is completely abolished when riboflavin (B2) and folate status are replete.

COMT Val158Met: Prefrontal Dopamine & Catechol Estrogen Detoxification

Catechol-O-methyltransferase (COMT) transfers a methyl group from SAMe to inactivate catecholamines (dopamine, norepinephrine, epinephrine) in the prefrontal cortex (which lacks high-density dopamine transporters) and to methylate 2-hydroxyestradiol ($2{\text{-OHE}}_2$) and 4-hydroxyestradiol ($4{\text{-OHE}}_2$) into protective methoxyestrogens ($2{\text{-MeOE}}_2$).

• Slow COMT (Met/Met, A/A): Exhibits $3–4\times$ lower enzymatic stability at body temperature. Carriers enjoy superior baseline working memory and executive attention under calm conditions due to high tonic prefrontal dopamine, but suffer rapid cognitive degradation under acute stress, sleep deprivation, or dopaminergics/stimulants (“inverted-U” dopamine curve), as well as slower clearance of catechol estrogens and stress-induced norepinephrine.
• Methyl Donor Sensitivity: Slow COMT (Met/Met) individuals frequently experience anxiety, insomnia, or irritability when given high doses of methylated B-vitamins (5-MTHF, methylcobalamin) because rapid SAMe surges accelerate catecholamine synthesis faster than slow COMT can clear it.

Choline Shunt (PEMT) & Phase II Glutathione Conjugation (GSTM1/GSTP1)

When folate-dependent methylation (MTHFR/MTR) is impaired, the liver upregulates the parallel BHMT (betaine-homocysteine methyltransferase) pathway, consuming choline and betaine (TMG) to remethylate homocysteine. Individuals carrying both MTHFR 677T and PEMT rs7946 T/T (which impairs endogenous phosphatidylcholine synthesis) rapidly develop choline depletion, impaired VLDL export, and non-alcoholic fatty liver disease (MASLD) unless dietary choline ($>550–800\text{ mg/day}$) and TMG are supplied. Meanwhile, GSTM1 null (~45–50% of Caucasians/Asians) abolishes cytosolic mu-class glutathione S-transferase activity, increasing susceptibility to polycyclic aromatic hydrocarbons, heavy metals (mercury/arsenic), and lipid peroxides.

---

3. Root Causes of Phenotypic Decompensation

Genotype is constitutional susceptibility, not destiny. Decompensation occurs when SNPs collide with environmental stressors:

• Synthetic Folic Acid Overload: Unmetabolized folic acid (UMFA) from fortified refined grains competitively binds dihydrofolate reductase (DHFR) and folate receptors, paradoxically worsening functional 5-MTHF availability in MTHFR variants.
• Cofactor Depletion: Low dietary riboflavin (organ meats, eggs, dairy), magnesium (required for both MAT1A SAMe synthesis and COMT catalytic activity), or zinc/B6.
• High Xenobiotic / Estrogen Load: Mold mycotoxins, pesticides, alcohol, or exogenous estrogens overwhelming COMT and GSTM1 conjugation capacity.

---

4. Actionable Interventions

Foundational Protocols (01 - Foundations)

• Genotype-Matched Nutritional Architecture: Prioritize natural food folates (dark leafy greens, liver), choline-rich egg yolks ($140\text{ mg}$ choline/yolk for PEMT carriers), and cruciferous sulforaphane (broccoli sprouts to induce Nrf2 and compensate for GSTM1 deletion via GSTA/GSTP upregulation) per Macronutrient & Micronutrient Optimization.
• Autonomic Stress Buffering for Slow COMT (Met/Met): Prevent catecholamine overflow using Breathwork Protocols, NSDR & Neuroplasticity, and strict stimulant curfews.

Molecular & Pharmacological Interventions (02 - Compounds & Molecules)

• MTHFR C677T Riboflavin Protocol: Supplement Riboflavin / Riboflavin-5’-Phosphate ($10–50\text{ mg/day}$) alongside L-5-MTHF ($400–800\mu \text{g}$) and Trimethylglycine (TMG $1–2\text{ g/day}$) via Methylation & B-Complex.
• Slow COMT (Met/Met) Modification: Use Magnesium Glycinate/L-Threonate ($400\text{ mg}$) (obligate cofactor for COMT; Magnesium Forms & Bioavailability), Creatine ($5\text{ g/day}$) (Creatine & Phosphocreatine System to spare SAMe without driving catecholamine spikes), and prefer hydroxocobalamin/adenosylcobalamin + folinic acid if sensitive to methylfolate/methylcobalamin. Avoid catechol-structure polyphenols (high-dose EGCG/quercetin) that competitively inhibit COMT if experiencing catecholamine excess.
• GSTM1 Null / SOD2 Val/Val Antioxidant Defense: Support glutathione pools with GlyNAC (N-Acetylcysteine + Glycine via Amino Acids & Precursors) and sulforaphane glucosinolate.

---

5. Key Scientific Evidence Summary

• McNulty et al. (2006, Circulation) & Horigan et al. (2010, J. Hypertension): Proved in randomized trials that low-dose riboflavin ($1.6\text{ mg/day}$) selectively lowers homocysteine by 22% and reduces systolic blood pressure by 9–13 mmHg specifically in MTHFR 677TT homozygotes.
• da Costa et al. (2006, AJCN): Demonstrated that 78–80% of carriers of the PEMT rs12325817/rs7946 variant develop organ dysfunction (fatty liver/muscle damage) under low dietary choline.
• Egan et al. (2001, PNAS): Landmark study establishing the effect of COMT Val158Met on prefrontal physiology, dopamine catabolism, and working memory efficiency.

See full bibliographic details and quantitative effect sizes in Methylation & Detox SNPs (MTHFR, COMT, GST) - References.